Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2194–2196. doi: 10.1128/aac.38.9.2194

Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993.

J S Knapp 1, J A Washington 1, L J Doyle 1, S W Neal 1, M C Parekh 1, R J Rice 1
PMCID: PMC284710  PMID: 7811045

Abstract

Twenty-five isolates of beta-lactamase-negative strains of Neisseria gonorrhoeae exhibiting decreased susceptibilities to ciprofloxacin (MIC, > or = 0.125 microgram/ml) were isolated from men with uncomplicated gonococcal urethritis in Cleveland, Ohio, from January 1992 through June 1993. The strains belonged to three auxotype-serovar classes: Pro-IB-1 (2 isolates), Pro-IB-2 (21 isolates), and Pro-IB-3 (2 isolates). MICs for strains were in the intermediate or resistant categories for penicillin, the intermediate or susceptible categories for tetracycline (with the exception of one strain that had acquired the 25.2-MDa TetM-containing plasmid) and cefoxitin, and the susceptible categories for ceftriaxone and cefixime (MICs, < or = 0.25 microgram/ml) and spectinomycin (MIC, < or = 256 micrograms/ml). MICs for strains were also in the susceptible category for ofloxacin (MIC, 0.25 microgram/ml) and in categories higher than susceptible for ciprofloxacin (MICs, 0.125 to 0.25 microgram/ml) and ofloxacin (MIC, 0.5 microgram/ml). The diameters of zones of inhibition for these strains ranged from 31 to 39 mm for ciprofloxacin to 28 to 35 mm for ofloxacin. The persistence of these strains over an 18-month period supports the need for routine sentinel surveillance and monitoring of gonococcal isolates, particularly posttreatment isolates, for resistance to quinolones when these agents are used for the primary therapy of uncomplicated gonorrhea.

Full text

PDF
2194

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clendennen T. E., Echeverria P., Saengeur S., Kees E. S., Boslego J. W., Wignall F. S. Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob Agents Chemother. 1992 Aug;36(8):1682–1687. doi: 10.1128/aac.36.8.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gorwitz R. J., Nakashima A. K., Moran J. S., Knapp J. S. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ. 1993 Aug 13;42(3):29–39. [PubMed] [Google Scholar]
  4. Gransden W. R., Warren C. A., Phillips I., Hodges M., Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet. 1990 Jan 6;335(8680):51–51. doi: 10.1016/0140-6736(90)90177-7. [DOI] [PubMed] [Google Scholar]
  5. Jephcott A. E., Turner A. Ciprofloxacin resistance in gonococci. Lancet. 1990 Jan 20;335(8682):165–165. doi: 10.1016/0140-6736(90)90035-4. [DOI] [PubMed] [Google Scholar]
  6. Knapp J. S., Tam M. R., Nowinski R. C., Holmes K. K., Sandström E. G. Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J Infect Dis. 1984 Jul;150(1):44–48. doi: 10.1093/infdis/150.1.44. [DOI] [PubMed] [Google Scholar]
  7. Putnam S. D., Lavin B. S., Stone J. R., Oldfield E. C., 3rd, Hooper D. G. Evaluation of the standardized disk diffusion and agar dilution antibiotic susceptibility test methods by using strains of Neisseria gonorrhoeae from the United States and Southeast Asia. J Clin Microbiol. 1992 Apr;30(4):974–980. doi: 10.1128/jcm.30.4.974-980.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rice R. J., Knapp J. S. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes. Antimicrob Agents Chemother. 1994 Jan;38(1):155–158. doi: 10.1128/aac.38.1.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Schwarcz S. K., Zenilman J. M., Schnell D., Knapp J. S., Hook E. W., 3rd, Thompson S., Judson F. N., Holmes K. K. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA. 1990 Sep 19;264(11):1413–1417. [PubMed] [Google Scholar]
  10. Short H. B., Ploscowe V. B., Weiss J. A., Young F. E. Rapid method for auxotyping multiple strains of Neisseria gonorrhoeae. J Clin Microbiol. 1977 Sep;6(3):244–248. doi: 10.1128/jcm.6.3.244-248.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Whittington W. L., Knapp J. S. Trends in resistance of Neisseria gonorrhoeae to antimicrobial agents in the United States. Sex Transm Dis. 1988 Oct-Dec;15(4):202–210. doi: 10.1097/00007435-198810000-00006. [DOI] [PubMed] [Google Scholar]
  12. van der Willigen A. H., van der Hoek J. C., Wagenvoort J. H., van Vliet H. J., van Klingeren B., Schalla W. O., Knapp J. S., van Joost T., Michel M. F., Stolz E. Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrob Agents Chemother. 1987 Apr;31(4):535–538. doi: 10.1128/aac.31.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES